quotes and stock data may be delayed 15 minutes
52 wk low
52 wk hi
Burn Rate (Qtr)
Click on drug name or indication to see upcoming trial info, prior data, and more general information.
No drug found
We have found any drug for this company yet
Drug | Disease (links)
Stage (next event)
search in progress
Pipeline powered by
DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company's lead drug candidate is in clinical development for the potential treatment of alcoholic hepatitis (AH), COVID-19 patients with acute liver or kidney injury, and nonalcoholic steatohepatitis (NASH).
See what the community is saying - click to see full post.